www.pharmablog.nl

Weblog met nieuws over de pharmaceutische industrie

Archive for September, 2009

Onyx starts filling tumor trial

Onyx Pharmaceuticals Inc. started enrolling patients in a Phase I trial of a drug that could treat advanced solid tumors. (ONXX)

Lees meer..

  • 0 Comments
  • Filed under: 3
  • Cerner Corp. and the University of Missouri announced plans Monday to create a Tiger Institute for Health Innovation, which is expected to generate revenue for Cerner, save money for the university and potentially reduce health care costs statewide.

    Lees meer..

  • 0 Comments
  • Filed under: 3
  • Carolinas HealthCare System and Novant Health Inc. will not allow visitors under 18 at their Charlotte-area hospitals, effective Thursday.

    Lees meer..

  • 0 Comments
  • Filed under: 3
  • Trinity Medical Center said Monday it will have to close if it is not allowed to relocate to U.S. 280 while two competitors claim the move would financially devastate them.

    Lees meer..

  • 0 Comments
  • Filed under: 3
  • Chance Phillips is the new chief financial officer at Oak Hill Hospital in Spring Hill.

    Lees meer..

  • 0 Comments
  • Filed under: 3
  • Children’s Hospital has handed out its first round of funding from a newly launched technology development fund. The awards are designed to spur research into “potentially life saving products”, Children’s officials said. The awards support efforts that range from pharmaceuticals and diagnostics and medical devices to vaccines and tissue engineering.

    Lees meer..

  • 0 Comments
  • Filed under: 3
  • REM, Sleep HealthCenters merge

    REM Medical Corp., with operations in Arizona and Seattle, and New England’s Sleep HealthCenters LLC have merged.

    Lees meer..

  • 0 Comments
  • Filed under: 3
  • University Hospital has hired the former CEO of St. Luke Hospitals as its executive operations director.

    Lees meer..

  • 0 Comments
  • Filed under: 3
  • The patient is still in the operating room, and the prognosis is not good.

    Lees meer..

  • 0 Comments
  • Filed under: 3
  • Seattle biotechnology company ZymoGenetics Inc. said Monday that Merck Serono SA had decided to halt studies of ZymoGenetics’ drug candidate atacicept for treatment of multiple sclerosis. (ZGEN)

    Lees meer..

  • 0 Comments
  • Filed under: 3